If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That would be on that 12 pence worth at .22 the mm's trying hard :.)
Nonsense marking it up blue today.Means sweet fanny adams
"Are you sure you're looking at NFX?"
Strangely yes when I refer to NFX I was actually looking at NFX. It started at 0.18 was was up to 0.22 early doors, it then dropped back to 0.18.
PS I also meant to say that if the Ctte for the orphan application raises questions does the stock answer take priority ie the company is focusing on licensing discussions and will the orphan answers have to wait.
Soups last post was 13/3, the day before the last RNS from the co. He is not dealing with the licensees is he?
FX I see Olders post was 29th Feb which was only about 7 weeks ago. I read through his other notes at the time, co seemed keen to submit the orphan application at that point with an eta of 90 days so the end of May, that allows for questions from the Ctte. 7 weeks is not a long time for any govt dept so it may just require patience.
The only comment I have, is the stock answer from the co atm gives the impression that the only priority is liscensing discussions which suggests they are fully occupied. If the ctte raises questions on the application that extends the approval from 60 days to 90 days. I don’t think there is any doubt that IPF is a rare disease so it might be a cart and horse issue.
Does anyone else have an explanation for this?
Where is Soup?
"I do notice however a nice rise this morning, someone is interested in buying into NFX :)"
Are you sure you're looking at NFX?
Unless I'm missing something the bid is 0.18p and the ask is 0.22p - down -2.7% with a total of 112,466 shares traded (about £225)
I did not get a response, yet.
I do notice however a nice rise this morning, someone is interested in buying into NFX :)
Back on 29th Feb, OlderButWiser kindly shared a rough transcript of the communication as presented to the Telegram group in which the following points were highlighted:
"• EU patent for 002 is in process of finalisation and will be announced imminently.
• Orphan drug status application submission.
• 004 patents progress and update
• The NEW plan mentioned by Dan, whatever that is, to promote company based upon BD progress and the massive potential (his words) they see.
• The company will update with company presentation soon."
Has ANY of this actually come to pass?
If the EU patent was supposed to be in the process of finalisation, why has nothing been announced in the nearly 2 months since? They could have been over half way through the orphan status process in that time.
Why does the company have nothing to say?
Transhaven, did you get a response to your email?
The point is they can set forth a plan of action - ie we are going to solidify our patent portfolio by taking additional filings, without being obliged to inform shareholders along each step of the way. Dan suggests applying for orphan status is necessary for 002, but did not indicate he would inform us when NFX applied (as with patent filings), & I for one leaving the discussion, had no expectation one would be forthcoming. Storm in a tea cup, nothing is happening till the summer........
I know they are not obligated to supply such information but you are missing the point. If they are so keen to tell us they are going to apply where is the harm in answering a simple question on whether they have done so or not.
Anyway, we are going round in circles . Some believe it's odd they won't answer yes or no and others think it's fine to mention it then clam up about it.
Dan went on telegram solely to schmooze and get the AGM resolutions over the line,and the money raised was for wages,not some further work on the assets.Its a waiting game for deals.I can’t see the orphan drug route holding sway, if someone is going to sign or buy the assets,they will.They can always apply for that themselves.They have supposedly been in talks a while,so what’s the hold up,they either want them or they don’t,NFX aren’t in a position to play hard ball.
If you want to know Dan's rationale FFX thats a question for him not me.
"No Chab there is no obligation on them to inform shareholders every time they file for a patent, orphan status or a grant."
By the same rule Jiving, If that really is a Nuformix representative then why do they feel obliged to share the company's intentions via a limited confab on Telegram?
Replace first bit with
t me /
tg link: *************nuformixnfx
No Chab there is no obligation on them to inform shareholders every time they file for a patent, orphan status or a grant. They haven't in the past so why should they now?
Looks like someone doesn't like the lack of info - big drop this morning.
Can I have a link to the telegram group
"I didnt expect there to be any announcement of them filing for that status"
Without wanting to seem argumentative that just doesn't hold water. The are quite happy to tell the world that they intend to apply for such status but then don't seem to want to tell pi's whether they have done so. Seems very picky about what they wish to divulge even though Dan appears to enjoy a chat on Telegram.
ATB
Good link Mars, there is a lot of money available for the right deals - does that include ours?
I also agree that the orphan status appeared from Dan's TG discussion to be a necessary condition for making progress. I could see from the Pharma's perspective why they would require this form of elementary 'free' filtering of potential candidates. I didnt expect there to be any announcement of them filing for that status, just as they dont announce in advance when they file patent claims in US/Japan etc. I would hope for an update in the summer if the orphan status is awarded & it would be natural then to set out the path ahead for the rest of the year. I dont have any expectation of news until then.
Pre-AGM all rumour pointed towards orphan status being the key to any deal. So either that was all BS and they haven't submitted it or they don't want to announce that they have. I don't know the answer to that.
What is remarkably strange though is that there is a deafening silence from a number of individuals who would normally be very quick to pour cold water on anyone suggesting that things might not be moving along. Again, I have no idea why. Hopefully they are all in good health. It just seems unusually strange that they don't have anything at all to say.
One question does arise is what keeps you so busy you cannot multitask ie pursue orphan status in addition to outlicensing. A huge part of the process is due diligence but providing data to be analysed by the counterparts does not create that pressure there are periods of high activity and then awaiting the outcome from activity from the other side of the fence. There may be other requirements that exist but full blown involvement is required looking at alternative results or legal agreements. Wishful thing I know
We certainly would but the reply from donttelltoomuchTim indicates they are too busy dealing with licensing to pursue the orphan application atm
Mars,
Isn't that what we all believed the board to be doing for the last year or more?
It would be nice to know who exactly they have talking to.
PWC need to tell AZ
“Biotech acquisitions to fend off patent cliffs: Large-cap pharma companies will continue to face patent cliffs and gaps in their pipelines in the latter half of this decade and will look for M&A opportunities to achieve their growth plans. Small and midsize biotech companies that can fill in pipeline gaps in the back half of the decade will receive significant attention in 2024. However, the threshold rates of return which these acquisition targets must clear are now higher because of higher risk-free interest rates; as such, the competition will be fierce for truly innovative targets whose clinical differentiation is backed by good data.”
https://www.pwc.com/gx/en/services/deals/trends/health-industries.html